[Pharmacokinetic and clinical research on a new aminoglycoside antibiotic: sisomicin]. 1978

F Di Nola, and M L Soranzo, and G Bosio, and N Sachelariu, and C Guasco, and L Bendiscioli, and I Bisarello

Results obtained with sisomycin in 10 cases of purulent meningitis and 4 of bronchopulmonitis showed good tissue diffusion, together with CSF concentrations sufficient to inhibit the main aetiological agents in these forms: MIC 0.02 mg/ml for both D. pneumoniae (I-ATCC 6301) and N. meningitidis (C-ATCC 13101), i.e. liquor transfer of the antibiotic more than sufficient to handle these agents.

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008581 Meningitis Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6) Pachymeningitis,Meningitides,Pachymeningitides
D008589 Meningococcal Infections Infections with bacteria of the species NEISSERIA MENINGITIDIS. Meningococcal Septicemia,Infections, Meningococcal,Meningococcal Disease,Infection, Meningococcal,Meningococcal Diseases,Meningococcal Infection,Septicemia, Meningococcal
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011008 Pneumococcal Infections Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE. Streptococcus pneumoniae Infections,Infections, Pneumococcal,Infections, Streptococcus pneumoniae,Pneumococcal Diseases,Disease, Pneumococcal,Diseases, Pneumococcal,Infection, Pneumococcal,Infection, Streptococcus pneumoniae,Pneumococcal Disease,Pneumococcal Infection,Streptococcus pneumoniae Infection
D001996 Bronchopneumonia Inflammation of the lung parenchyma that is associated with BRONCHITIS, usually involving lobular areas from TERMINAL BRONCHIOLES to the PULMONARY ALVEOLI. The affected areas become filled with exudate that forms consolidated patches. Bronchial Pneumonia,Bronchial Pneumonias,Bronchopneumonias,Pneumonia, Bronchial,Pneumonias, Bronchial
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children

Related Publications

F Di Nola, and M L Soranzo, and G Bosio, and N Sachelariu, and C Guasco, and L Bendiscioli, and I Bisarello
November 1977, La Clinica terapeutica,
F Di Nola, and M L Soranzo, and G Bosio, and N Sachelariu, and C Guasco, and L Bendiscioli, and I Bisarello
November 1976, The Journal of infectious diseases,
F Di Nola, and M L Soranzo, and G Bosio, and N Sachelariu, and C Guasco, and L Bendiscioli, and I Bisarello
January 1975, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
F Di Nola, and M L Soranzo, and G Bosio, and N Sachelariu, and C Guasco, and L Bendiscioli, and I Bisarello
February 1975, The Journal of antibiotics,
F Di Nola, and M L Soranzo, and G Bosio, and N Sachelariu, and C Guasco, and L Bendiscioli, and I Bisarello
June 1974, Antimicrobial agents and chemotherapy,
F Di Nola, and M L Soranzo, and G Bosio, and N Sachelariu, and C Guasco, and L Bendiscioli, and I Bisarello
September 1983, Masui. The Japanese journal of anesthesiology,
F Di Nola, and M L Soranzo, and G Bosio, and N Sachelariu, and C Guasco, and L Bendiscioli, and I Bisarello
December 1972, The Japanese journal of antibiotics,
F Di Nola, and M L Soranzo, and G Bosio, and N Sachelariu, and C Guasco, and L Bendiscioli, and I Bisarello
February 1978, Journal of medicinal chemistry,
F Di Nola, and M L Soranzo, and G Bosio, and N Sachelariu, and C Guasco, and L Bendiscioli, and I Bisarello
August 1975, The Journal of antibiotics,
F Di Nola, and M L Soranzo, and G Bosio, and N Sachelariu, and C Guasco, and L Bendiscioli, and I Bisarello
January 1981, The Journal of international medical research,
Copied contents to your clipboard!